FDA Signals Positive Shift on Peptides—But the Fight Is Far From Over
The current leadership of FDA may be softening its stance on peptides—but past patterns suggest the outcome is far from certain. Action Alert! Listen to the audio version of this article: THE TOPLINE Access to some of the most promising emerging therapies in modern medicine is in peril. Behind the scenes, federal regulators are making […]








